Causal role of phenylalanine and cholesterol metabolism in bladder cancer Chemoresistance: Insights from mendelian randomization and targeted molecular docking
Archives of Biochemistry and Biophysics · 2025
DOI: 10.1016/j.abb.2025.110530 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2025. Verfasst von Junyu Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Fourth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 511300, China. Hauptthemen laut MEDLINE: Cholesterol, Urinary Bladder Neoplasms, Drug Resistance, Neoplasm, Phenylalanine. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Guangzhou Science, Technology and Innovation Commission, Guangzhou Municipal Science and Technology Program key projects.
Abstract (Originalsprache)
Bladder cancer (BLCA) exhibits profound chemoresistance, partly mediated by metabolic dysregulation. This study investigated the roles of phenylalanine (Phe) and cholesterol metabolism in BLCA chemoresistance using integrated omics and computational modeling. Transcriptomic analysis of the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets revealed that elevated hexokinase 2 (HK2) and low-density lipoprotein receptor (LDLR) expression correlates with poor response to cisplatin. Mechanistically, Phe catabolism via phenylalanine hydroxylase (PAH) activated mTORC1 signaling, promoting glycolysis and drug efflux, while cholesterol biosynthesis driven by SREBP2 enhanced ABCG2 transporter activity. Mendelian randomization (MR) analyses confirmed causal associations between Phe/cholesterol metabolism and chemoresistance risk. Pharmacological inhibition of HMG-CoA reductase or dietary phenylalanine restriction sensitized BLCA cells to cisplatin both in vitro and in xenograft models. Overexpression of FOLH1 or F7 reversed the inhibitory effects of Phe or cholesterol targeting, respectively, confirming their functional roles in resistance. These findings identify FOLH1 and F7 as mediators of metabolic resistance in BLCA and suggest metabolic targeting as a promising therapeutic strategy. However, whether combined inhibition of Phe and cholesterol pathways provides synergistic benefits over monotherapy remains to be determined in future studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Fourth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 511300, China.
- Department of Cancer Chemotherapy, The Fourth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 511300, China.
- Department of Neurology, The Fourth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 511300, China. Electronic address: jinlium2012@163.com.
- Department of Cancer Chemotherapy, The Fourth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 511300, China. Electronic address: yangguangda2010@126.com.
Förderung
- Guangzhou Science, Technology and Innovation Commission
- Guangzhou Municipal Science and Technology Program key projects
Zitieren
APA
Li, J., Chen, Q., Wang, J., Wang, Z., Jian, L., & Yang, G. (2025). Causal role of phenylalanine and cholesterol metabolism in bladder cancer Chemoresistance: Insights from mendelian randomization and targeted molecular docking. Archives of Biochemistry and Biophysics. https://doi.org/10.1016/j.abb.2025.110530
Vancouver
Li J, Chen Q, Wang J, Wang Z, Jian L, Yang G. Causal role of phenylalanine and cholesterol metabolism in bladder cancer Chemoresistance: Insights from mendelian randomization and targeted molecular docking. Archives of Biochemistry and Biophysics. 2025. doi:10.1016/j.abb.2025.110530
BibTeX
@article{Li2025,
author = {Li, Junyu and Chen, Qianya and Wang, Jing and Wang, Zhichao and Jian, Liumeng and Yang, Guangda},
title = {Causal role of phenylalanine and cholesterol metabolism in bladder cancer Chemoresistance: Insights from mendelian randomization and targeted molecular docking},
journal = {Archives of Biochemistry and Biophysics},
year = {2025},
doi = {10.1016/j.abb.2025.110530}
}
EUVIMED